Antibiotics business: A glimpse

Indian Journal of Biotechnology

Volumn 5, Issue 4, 2006, Pages 471-476

  Bhattacharyya, B K ^a   Sen, S K ^b  

^a East India Pharmaceutical Works Limited   (India)

^b VISVA BHARATI UNIVERSITY   (India)

Author keywords

Antibiotic; Broad spectrum; Business; Pharmaceutical industry; Streptomyces

Indexed keywords

2 PYRIDONE DERIVATIVE; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZITHROMYCIN; BACITRACIN; BENOMYL; CEPHALOSPORIN; CHLORAMPHENICOL; CYCLOSERINE; DACTINOMYCIN; ERYTHROMYCIN; ETICYCLIDINE; FUSIDIC ACID; GATIFLOXACIN; GRAMICIDIN; KETOLIDE; LINCOMYCIN; MONENSIN; NYSTATIN; ORITAVANCIN; PENICILLIN G; POLYMYXIN; PUROMYCIN; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; TERBINAFINE; TETRACYCLINE; VANCOMYCIN;

BACTEREMIA; BACTERIAL INFECTION; CLINICAL TRIAL; DNA REPLICATION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; HUMAN; MORTALITY; MYCOSIS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SURVIVAL RATE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

STREPTOMYCES;

EID: 33845258758     PISSN: 09725849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Demain A L, Small bugs, big business: The economic power of the microbe, Biotechnol Adv, 18 (2000) 499-514.
2. Berdy J, Microbial secondary metabolites play important roles in medicine: Prospects for discovery of new drugs, Perspect Biol Med, 40 (1995) 364-394.
3. Strohl W R, Industrial antibiotics: Today and the future, in Biotechnology of antibiotics, 2nd edn, edited by W R Strohl (Marcel Dekker, New York) 1997, 1-47.
4. Demain A L, Pharmaceutically active secondary metabolites, Appl Microbiol Biotechnol, 52 (1999) 455-463.
5. Bentley R, Secondary metabolite biosynthesis: The first century, Crit Rev Biotechnol, 19 (1999) 1-40.
6. Wenzel R P, The antibiotic pipeline-challenges, costs and values, N Eng J Med, 351 (2004) 523-526.
7. Demain A L, Microbial biotechnology, Trends Biotechnol, 18 (2000) 26-31.
8. Persidis A, Antibacterial and antifungal drug discovery, Nat Biotechnol, 17 (1999) 1141-1142.
9. Sanglier J J, Haag H, Huck T A & Fehr T, Review of anctimomycetes compounds 1990 -1995. Exp Opin Invest Drugs, 5 (1996) 207-233.
10. Davey P G, Malek M M & Parker S E, Pharmacoecoconomics of antibacterial treatment, Pharmacoecoconomics, 1 (1992) 409-437.
11. Strohl W R, Secondary metabolites, in Encyclopedia of bioprocess technology: fermentation, biocatalysis and bioseparations, edited by M C Flicking and S W Drew (Wiley, New York) vol 5 (1999) 2348-2365.
12. Tally F A, Wendler P A & Houman F, Translation targets for antifungal drug development, Abstr, 5th Int Conf Biotechnology of Microbial Products: Novel Pharmacological and Agrobacterial Activities, Williamsburg, Va, (1997) 19.
13. Elander R P, Industrial production of β lactam antibiotics, Appl Microbiol Biotechnol, 61 (2003) 385-392.
14. Dasgupta F, Antifungal agents-past, present and future possibilities, in Antifungal agents past, present, future prospects, edited by R S Varma, I K Khan & A P Singh (National Academy of Chemistry and Biology, Lucknow) 1998, 29-54.
15. Pathak A N, Antifungal agents to manage mycotic infections, in Antifungal agents past, present, future prospects, edited by R S Verma, I K Khan & A P Singh (National Academy of Chemistry and Biology, Lucknow), 1998, 149-186.
16. Khan Z K & Gyanchandani A, Trends in antifungals: past, present and future, in Antifungal agents past, present, future prospects, edited by R S Verma, I K Khan & A P Singh (National Academy of Chemistry and Biology, Lucknow), 1998, 55-128.
17. Brown K S, Pharmaceutical and biotech firms taking on drug resistant microbes, The Scientist, 10 (1996) 1-9.
18. Barber M, in The penicillin business (Michael Barber & Associates, Catterham, Surrey, UK), 1996.
19. Barber M, in The cephalosporin business: 2000 and beyond, (Michael Barber & Associates, Catterham, Surrey, UK), 2000.
20. Van der Beck C P & Roels J A, Penicillin production: Biotechnology at its best, Antonie van Leeuwenhoek, 50 (1984) 625-639.
21. Elander R P & Chiang S J, Genetics and antibiotic process improvement: From classical genetics to genetic engineering, in Recombinant DNA technology and applications, edited by A Procop, R K Bajpai & C Ho (McGraw Hill, New York), 1991, 133-170.
22. Sylvester J C & Coghill R D, The penicillin fermentation, in Industrial fermentations, vol. 2, edited by L A Underkofler & R J Hickey (Chemical Publishing, New York), 1954, 219-263.
23. Stewart J J, Allison P N & Johnson R S, Putting a price on biotechnology, Nat Biotechnol, 19 (2001) 813-817.
24. Projan S J, Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol, 6 (2003) 427-430.
25. Preziosi P, Science, pharmacoeconomics and ethics in drug R&D: A sustainable future scenario? Nat Rev Drug Discovery, 3 (2004) 521-526.
26. Reichert J M, Trends in development and approval for the new therapeutics in the United States, Nat Rev Drug Discovery, 2 (2003) 695-702.
27. Stapley E O, Jackson M, Hernandez S, Zimmerman S B, Currie S A et al, Cephamycins, a new family of β lactam antibiotics. 1: Production by actinomycetes, including Streptomyces lactamdurams sp n, Antimicrob Agents Chemother, 2 (1972) 122-131.
28. Hendlin D, Stapley E O, Jackson M, Wallick H, Miller A K, Wolf F J et al, Phosphomycin: A new antibiotic produced by strains of Streptomyces, Science, 166 (1969) 122-123.
29. Birnbaum J, Kahan F M, Kropp H & Mac Bonald J S, Carbapenems, a new class of β lactam antibiotics: Discovery and development of imipenem/cilastatin, Am J Med, 78 suppl, 6A (1985) 3-21.
30. Shedge S & Krishnan V, The Indian pharmaceutical and biotech industry: The road ahead, Pharma Bio World, 3 (2004) 83-90.
31. Gupte M, Kulkarni P & Ganguli B N, Antifungal antibiotics, Appl Microbiol Biotechnol, 58 (2002), 46-57.
32. Claude J R, Les etudes de securite des produits en development dans industric pharmaceutique, Ann Pharma Fr, 59 (2001) 324-330.